Clinical definition of COPD exacerbations and classification of their severity

Southern Medical Journal

Volumn 102, Issue 3, 2009, Pages 277-282

  Caramori, Gaetano ^a   Adcock, Ian M ^b   Papi, Alberto ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b NONE

Author keywords

Clinical trials; COPD; Definition; Exacerbation; Severity

Indexed keywords

ANTIBIOTIC AGENT; GLUCOCORTICOID; ANTIINFECTIVE AGENT;

ASTHMA; BACTERIAL INFECTION; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL RESEARCH; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; HUMAN; MEDICAL PRACTICE; PRACTICE GUIDELINE; PROPHYLAXIS; REVIEW; VIRUS INFECTION; ARTICLE; CHRONIC BRONCHITIS; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; HOSPITALIZATION; MICROBIOLOGY; PHYSICAL EXAMINATION; SPUTUM;

ANTI-BACTERIAL AGENTS; BRONCHITIS, CHRONIC; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HOSPITALIZATION; HUMANS; PHYSICAL EXAMINATION; PRACTICE GUIDELINES AS TOPIC; SEVERITY OF ILLNESS INDEX; SPUTUM;

EID: 63149093089     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e3181836b73     Document Type: Review

References (57)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Bethesda, National Heart, Lung and Blood Institute, April 2001; NIH Publication No. 2701: 1-100. Last update 2008. Available at: http://www.goldcopd.com. Accessed December 29, 2008.
2. O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Can Respir J 2007;14(suppl B):5B-32B. (Pubitemid 350090390)
3. O'Donnell DE, Hernandez P, Kaplan A, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2008 update-highlights for primary care. Can Respir J 2008;15(suppl A):1A-8A. (Pubitemid 351566057)
4. O'Brien C, Guest PJ, Hill SL, et al. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000;55:635-642. (Pubitemid 30468217)
5. Scarduelli C, Ambrosino N, Confalonieri M, et al. Prevalence and prognostic role of cardiovascular complications in patients with exacerbation of chronic obstructive pulmonary disease admitted to Italian respiratory intensive care units. Ital Heart J 2004;5:932-938.
6. Lieberman D, Lieberman D, Gelfer Y, et al. Pneumonic vs nonpneumonic acute exacerbations of COPD. Chest 2002;122:1264-1270. (Pubitemid 35339539)
7. Ambrosetti M, Ageno W, Spanevello A, et al. Prevalence and prevention of venous thromboembolism in patients with acute exacerbations of COPD. Thromb Res 2003;112:203-207.
8. Erelel M, Cuhadaroglu C, Ece T, et al. The frequency of deep venous thrombosis and pulmonary embolus in acute exacerbation of chronic obstructive pulmonary disease. Respir Med 2002;96:515-518.
9. Rutschmann OT, Cornuz J, Poletti PA, et al. Should pulmonary embolism be suspected in exacerbation of chronic obstructive pulmonary disease? Thorax 2007;62:121-125. (Pubitemid 46271717)
10. Tillie-Leblond I, Marquette CH, Perez T, et al. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med 2006;144:390-396. (Pubitemid 46768160)
11. Ramanuja S, Mastronarde J, Dowdeswell I, et al. A 44-year-old man with suspected exacerbation of COPD and atrial fibrillation. Chest 2004;125:2340-2344. (Pubitemid 38788207)
12. Emerman CL, Cydulka RK. Evaluation of high-yield criteria for chest radiography in acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med 1993;22:680-684.
13. Sherman S, Skoney JA, Ravikrishnan KP. Routine chest radiographs in exacerbations of chronic obstructive pulmonary disease. Diagnostic value. Arch Intern Med 1989;149:2493-2496. (Pubitemid 19283206)
14. Caramori G, Papi A. Pathogenic link between chronic obstructive pulmonary disease and squamous cell lung cancer. Expert Rev Respir Med 2007;1:171-175.
15. Anthonisen NR, Manfreda J, Warren CPW, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204. (Pubitemid 17009877)
16. Thompson AB, Daughton D, Robbins RA, et al. Intraluminal airway inflammation in chronic bronchitis. Characterization and correlation with clinical parameters. Am Rev Respir Dis 1989;140:1527-1537. (Pubitemid 20041029)
17. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006;173:1114-1121. (Pubitemid 43726892)
18. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000;117(5 suppl 2):398S-401S. (Pubitemid 30314474)
19. Pauwels R, Calverley P, Buist AS, et al. COPD exacerbations: the importance of a standard definition. Respir Med 2004;98:99-107. (Pubitemid 38181126)
20. Currie GP, Wedzicha JA. ABC of chronic obstructive pulmonary disease. Acute exacerbations. BMJ 2006;333:87-89. (Pubitemid 44406817)
21. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-224. (Pubitemid 34162820)
22. Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial [Erratum in Lancet 2005;366:984]. Lancet 2005;365:1552-1560. (Pubitemid 40615404)
23. Fabbri LM, Beghè B, Caramori G, et al. Similarities and discrepancies between exacerbations of asthma and chronic obstructive pulmonary disease. Thorax 1998;53:803-808.
24. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-1303.
25. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-456. (Pubitemid 36173708)
26. Calverley P, Pauwels Dagger R, Lofdhal CG, et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD [Erratum in Eur Respir J 2006;27:440]. Eur Respir J 2005;26:406-413.
27. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:416-469.
28. Allegra L, Grassi C, Grossi E, et al. Ruolo degli antibiotici nel trattamento delle riacutizzazioni della bronchite cronica: risultati di uno studio italiano multicentrico. Ital J Chest Dis 1991;45:138-148.
29. Donaldson GC, Seemungal TA, Patel IS, et al. Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur Respir J 2003;22:931-936.
30. Seemungal TAR, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608-1613. (Pubitemid 30329036)
31. Connors AF, Dawson NV, Thomas C, et al. Outcomes following acute exacerbations of severe chronic obstructive lung disease [Erratum in Am J Respir Crit Care Med 1997;155:386]. Am J Respir Crit Care Med 1996;154(4 pt 1):959-967.
32. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J Suppl 2003;41:46s-53s.
33. Celli BR, Mac Nee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper [Erratum in Eur Respir J 2006;27:242]. Eur Respir J 2004;23:932-946.
34. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-789. (Pubitemid 46294610)
35. Niewoehner DE. The role of systemic corticosteroids in acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Med 2002;1:243-248. (Pubitemid 37038943)
36. Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;2:CD004403. (Pubitemid 46841358)
37. Cao Z, Ong KC, Eng P, et al. Frequent hospital readmissions for acute exacerbation of COPD and their associated factors. Respirology 2006;11:188-195. (Pubitemid 43356900)
38. Tsoumakidou M, Tzanakis N, Voulgaraki O, et al. Is there any correlation between the ATS, BTS, ERS and GOLD COPD's severity scales and the frequency of hospital admissions? Respir Med 2004;98:178-183. (Pubitemid 38181138)
39. Franciosi LG, Page CP, Celli BR, et al. Markers of exacerbation severity in chronic obstructive pulmonary disease. Respir Res 2006;7:74.
40. Muller B, Tamm M. Biomarkers in acute exacerbation of chronic obstructive pulmonary disease: among the blind, the one-eyed is king. Am J Respir Crit Care Med 2006;174:848-849. (Pubitemid 44564781)
41. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:1618-1623. (Pubitemid 33124148)
42. Caramori G, Ito K, Contoli M, et al. Molecular mechanisms of respiratory virus-induced asthma and COPD exacerbations and pneumonia. Curr Med Chem 2006;13:2267-2290. (Pubitemid 44184652)
43. Stockley RA, O'Brien C, Pye A, et al. Relationship to sputum colour to nature and out-patient management of acute exacerbations of COPD. Chest 2000;117:1638-1645. (Pubitemid 30413357)
44. Stockley RA. Chronic obstructive pulmonary disease, neutrophils and bacteria: from science to integrated care pathways. Clin Med 2004;4:567-572.
45. Sapley E, Stockley RA. COPD exacerbations. 2: aetiology. Thorax 2006;61:250-258.
46. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005;143:317-326. (Pubitemid 41266605)
47. Barnes PJ, Chowdhury B, Kharitonov SA, et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174:6-14. (Pubitemid 43955238)
48. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin- guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomized, single-blinded intervention trial. Lancet 2004;363:600-607. (Pubitemid 38264177)
49. Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin- guidance with standard therapy. Chest 2007;131:9-19. (Pubitemid 46122969)
50. Decramer M, Celli B, Tashkin DP, et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the uplift trial. COPD 2004;1:303-312.
51. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of COPD exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26.
52. Miravitlles M, Ferrer M, Pont A, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2-year follow up study. Thorax 2004;59:387-395. (Pubitemid 38624744)
53. Jones PW, Willits LR, Burge PS, et al. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003;21:68-73. (Pubitemid 36150303)
54. Gompertz S, Bayley DL, Hill SL, et al. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax 2001;56:36-41. (Pubitemid 32041717)
55. Contoli M, Caramori G, Mallia P, et al. A human rhinovirus model of chronic obstructive pulmonary disease exacerbations. Contrib Microbiol 2007;14:101-112.
56. Kharitonov SA, Barnes PJ. Lipopolysaccharide challenge of humans as a model for chronic obstructive lung disease exacerbations. Contrib Microbiol 2007;14:83-100.
57. Hoogerwerf JJ, de Vos AF, Bresser P, et al. Lung inflammation induced by lipoteichoic acid or lipopolysaccharide in humans. Am J Respir Crit Care Med 2008;178:34-41. (Pubitemid 351919191)